Antares Pharma has appointed Dr David Bergstrom as senior VP of pharmaceutical development.
Dr Bergstrom joins from Advantar Laboratories where he serves as executive VP and chief operating officer.
His previous roles included spells as chief operating office of NoveDel Pharmaceuticals and general manager of pharmaceutical development at Cardinal Health.
He is the second senior VP to join Antares this month after the appointment of former Pfizer VP Dr Bruce Freundlich as senior VP, medical.
The appointments come as the company looks to expand its business after the commercialisation of Otrexup (methotrexate) for arthritis and the advance in development of testosterone replacement therapy Vibex QS T.
Dr Paul Wotton, CEO of Antares, said: “David has a proven track record as a leader of product development teams and has worked on multiple FDA approved products including 505B2 drug/device combination programmes. His broad product development expertise will help drive our pipeline initiative.”